Genetics of hypertension. Therapeutic implications

Area of Science:

• Genetics
• Cardiovascular Medicine
• Pharmacology

Background:

• Essential hypertension impacts 20% of adults, stemming from complex gene-environment interactions.
• Understanding the molecular basis of hypertension is crucial for developing targeted therapies and reducing cardiovascular disease.
• While rare single-gene hypertension follows Mendelian inheritance, essential hypertension's complex genetics necessitate varied study designs.

Purpose of the Study:

• To explore the genetic underpinnings of essential hypertension.
• To investigate the role of genetic polymorphisms in blood pressure regulation and response to antihypertensive therapies.
• To identify potential targets for personalized antihypertensive treatments.

Main Methods:

• Review of studies on genetic polymorphisms in the renin-angiotensin system (RAS) and adrenergic receptors.
• Analysis of family-based association, affected sibling pair, and case-control studies.
• Examination of genetic variations like ACE gene polymorphisms and alpha-adducin gene variations.

Main Results:

• Polymorphisms in the renin-angiotensin system (RAS) show inconsistent associations with hypertension and antihypertensive response.
• Angiotensin converting enzyme (ACE) gene polymorphisms are linked to left ventricular hypertrophy but not clearly to hypertension itself.
• Genetic variations in adrenergic receptors are associated with blood pressure variability, and alpha-adducin gene polymorphisms may influence responses to diuretics.

Conclusions:

• Further research is needed to clarify the role of specific genetic polymorphisms in essential hypertension and antihypertensive drug response.
• Individualizing hypertension treatment based on genetic profiles holds promise for improving cardiovascular outcomes.
• Gene therapy for hypertension is not a near-term replacement for pharmacological approaches.